Redshiftbio provides automated analytical platforms that deliver real‑time, high‑precision biophysical data directly in native formulation buffers. Aurora TX uses microfluidic modulation spectroscopy for label‑free structural characterization, while HaLCon offers at‑line protein titer measurement with HPLC‑level accuracy, enabling faster decision‑making in biopharma development and manufacturing.
Funding
$5.9M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Biopharmaceutical development and manufacturing rely on slow, labor‑intensive analytical methods that require sample dilution, buffer exchange, or extensive expertise, creating bottlenecks in structural characterization and real‑time titer monitoring.
Solution
RedshiftBio offers two automated platforms that deliver rapid, high‑precision biophysical data directly in native formulation buffers. Aurora TX uses Microfluidic Modulation Spectroscopy (MMS) – a quantum‑cascade‑laser‑driven, microfluidic flow‑cell system – to generate high‑resolution infrared spectra of proteins, RNA, peptides, and complex biologics, detecting subtle structural changes with 30× greater sensitivity than traditional FTIR. HaLCon provides at‑line protein titer measurement with HPLC‑level accuracy in minutes, handling crude bioprocess samples without dilution. Both instruments feature real‑time background subtraction, walk‑away automation compatible with standard 96‑well plates, and integrated software that delivers quantitative results and trend analysis for immediate decision‑making in development and manufacturing workflows.
Target Audience
Primary customers are biopharma R&D and manufacturing teams—including process development scientists, formulation engineers, and analytical groups—who need fast, reliable structural and titer data for proteins, RNA therapeutics, peptides, and complex biologics.
Features
- Aurora TX: infrared‑based MMS combines a quantum cascade laser, precision microfluidic flow cell, and automated spectral analytics for label‑free secondary‑structure insight
- Detects structural shifts as small as those causing activity loss, aggregation, or binding changes across 0.1 mg/mL
- >200 mg/mL concentrations
- Real‑time buffer/background subtraction enables analysis in native formulation buffers without exchange or dilution
- Automated thermal ramping and 96‑well‑plate workflow provide walk‑away operation with >98 % reproducibility
- HaLCon: real‑time protein titer measurement with R² > 0.99 accuracy, delivering results in ~5 minutes
- Handles crude bioreactor samples (≈100 µL) without extensive preparation or method development
- Seamless integration with autosamplers (Nest Autosampler) for high‑throughput, multi‑plate processing
- Compact footprint suitable for both development labs and GMP‑compliant manufacturing suites